#pharmaceutical-tariffs

#pharmaceutical-tariffs

This week in Other Barks & Bites: news reports indicate that the Department of Justice's (DOJ's) Weaponization Working Group is looking into Biden-era secret review processes for pharmaceutical and AI patents at the U.S. Patent and Trademark Office (USPTO); the Federal Circuit corrects the Trademark Trial and Appeal Board's (TTAB's) application of the DuPont factors with regards to the scope of similar goods and services; USPTO Director John Squires signals a commitment to patent eligibility for medical diagnostics and crypto patents in his first few

President Trump outlined details of the framework trade deal with the EU, mentioning a small tariff on pharmaceuticals that will increase significantly over the next one to one and a half years.

"We are confident we will eclipse the savings the Biden administration achieved in the first year," the official said, indicating expectations for significant price reductions under the new plan.